Wall Street Zen Upgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to Strong-Buy

Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a report released on Saturday.

AMPH has been the subject of several other reports. Bank of America reissued an “underperform” rating and issued a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Barclays lowered their target price on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, June 3rd. Finally, Piper Sandler dropped their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Friday. Six equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $22.00.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $20.78 on Friday. The firm has a market cap of $883.98 million, a price-to-earnings ratio of 12.30, a PEG ratio of 4.39 and a beta of 0.89. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40. Amphastar Pharmaceuticals has a fifty-two week low of $16.65 and a fifty-two week high of $31.26. The firm has a 50 day moving average price of $19.66 and a 200-day moving average price of $21.36.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The company had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. As a group, equities research analysts forecast that Amphastar Pharmaceuticals will post 2.25 earnings per share for the current year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG purchased a new position in shares of Amphastar Pharmaceuticals in the second quarter valued at about $712,000. Bank of New York Mellon Corp bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $4,689,000. State of Wyoming purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth about $142,000. Pacer Advisors Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 47.1% during the first quarter. Pacer Advisors Inc. now owns 261,483 shares of the company’s stock worth $5,122,000 after purchasing an additional 83,739 shares during the period. Finally, Segall Bryant & Hamill LLC grew its stake in shares of Amphastar Pharmaceuticals by 197.9% in the first quarter. Segall Bryant & Hamill LLC now owns 33,318 shares of the company’s stock worth $653,000 after purchasing an additional 22,133 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Key Stories Impacting Amphastar Pharmaceuticals

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Amphastar reported second-quarter revenue of $183.9 million, exceeding analysts’ approximately $179.9 million estimate. Adjusted earnings were $0.91 per share, well above consensus estimates ranging from $0.62 to $0.66 and up from $0.85 a year earlier. GAAP net income totaled $30.3 million, or $0.67 per share, while adjusted net income was $40.8 million. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
• Positive Sentiment: The earnings beat was broad enough to attract attention from analysts, with coverage highlighting stronger-than-expected revenue, EPS and other key quarterly metrics. The results provide a positive near-term catalyst for AMPH and help support its valuation despite the stock remaining below its 200-day moving average. Amphastar Pharmaceuticals Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: Wells Fargo raised its price target from $19 to $20 but maintained an “equal weight” rating. The revised target remains below the recent trading level, signaling limited perceived upside despite the earnings performance. Wells Fargo price-target update
• Negative Sentiment: Piper Sandler lowered its price target from $21 to $20 and assigned a “neutral” rating. The downgrade in target suggests analysts remain cautious about AMPH’s outlook and could temper the positive reaction to the quarterly beat. Piper Sandler price-target update

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.